New Research on Lemtrada Reveals Insights into the Cause of Potential Side Effects

  • Researchers in the U.K. have evaluated additional findings about the immune-system impacts of Lemtrada®(alemtuzimab, Genzyme, a Sanofi Company), a disease-modifying therapy for treating people with relapsing MS.
  • The team used data from phase 3 clinical trials submitted to the European Medicines Agency during the drug’s successful approval process. Some of this data was previously reported at medical meetings and in Lemtrada’s prescribing information.
  • Among their findings, they report that Lemtrada caused long-term reduction of specific immune cells (memory B and T cells, including regulatory T cells). They also found…

    Favicon of da :

    Prosegui la lettura...
    Traduci l'articolo...

    Sclerosi Multipla News

    Potrebbe interessarti anche

Argomenti correlati